Abstract

Glioblastoma multiforme (GBM) is the most common and aggressive type of malignant glioma. Oncolytic adenoviruses are being modified to exploit the aberrant expression of proteins in tumor cells to increase the antiglioma efficacy. E1A mutant adenovirus Delta-24-RGD (DNX-2401) has shown a favorable toxicity profile and remarkable efficacy in a first-in-human phase I clinical trial. However, the comprehensive modulation of glioma metabolism in response to Delta-24-RGD infection is poorly understood. Integrating mass spectrometry based-quantitative proteomics, physical and functional interaction data, and biochemical approaches, we conducted a cell-wide study of cytosolic, nuclear, and secreted glioma proteomes throughout the early time course of Delta-24-RGD infection. In addition to the severe proteostasis impairment detected during the first hours post-infection (hpi), Delta-24-RGD induces a transient inhibition of signal transducer and activator of transcription 3 (STAT3), and transcription factor AP-1 (c-JUN) between 3 and 10hpi, increasing the nuclear factor kappa B (NF-κB) activity at 6hpi. Furthermore, Delta-24-RGD specifically modulates the activation dynamics of protein kinase C (PKC), extracellular signal–regulated kinase 1/2 (ERK1/2), and p38 mitogen-activated protein kinase (p38 MAPK) pathways early in infection. At extracellular level, Delta-24-RGD triggers a time –dependent dynamic production of multitasking cytokines, and chemotactic factors, suggesting potential pleiotropic effects on the immune system reactivation. Taken together, these data help us to understand the mechanisms used by Delta-24-RGD to exploit glioma proteome organization. Further mining of this proteomic resource may enable design and engineering complementary adenoviral based-vectors to increase the specificity and potency against glioma.

Highlights

  • Glioblastoma multiforme (GBM) is the most common and aggressive type of malignant glioma, characterized by infiltrative growth that cause progressive neurologic dysfunction [1]

  • Characterization of the early proteostasis impairment induced by Delta-24-RGD infection in glioma cells

  • Modulation of Non-POU domain-containing octamer-binding protein (NONO) expression during Delta-24-RGD infection was verified by Western blotting in nuclear extracts and in total cell extracts (Supplementary Figure 2), confirming the increment of this transcriptional regulator during the infection, and partially validating the quantitative LC-MS/MS approach used in this study

Read more

Summary

Introduction

Glioblastoma multiforme (GBM) is the most common and aggressive type of malignant glioma, characterized by infiltrative growth that cause progressive neurologic dysfunction [1]. A great effort is devoted to understanding the biology of glioma cells to develop treatment strategies against their molecular defects [3]. One of these approaches is oncolytic virotherapy, which uses replication-competent viruses to destroy cancer cells [4, 5]. Oncolytic adenoviruses are being modified to exploit the aberrant expression of proteins in tumor cells to enhance tumor tropism and glioma-selective replication [6]. Other trials for Delta24-RGD (DNX-2401) in combination with IFN-gamma, temozolomide or anti-PD1 antibody are currently active (Clinical-Trials.gov identifiers NCT02197169, and NCT02798406)

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call